Clinical trials · California
Allergy clinical trials in California
We’re tracking 37 recruiting allergy studies with a site in California — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06406114RecruitingPhase 2
Better Allergy Testing for Cephalosporin Antibiotics
This study tests better ways to diagnose allergies to common cephalosporin antibiotics, like Keflex and Rocephin. By participating, you may learn if you are truly allergic to these medicines and if they are safe for you to take in the future.
San Francisco, CaliforniaAges 18–70 - NCT07220811RecruitingPhase 2
Testing a new drug for food allergies
This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.
Palo Alto, CaliforniaAges 12–55 - NCT03539692Recruiting
Screening to join food allergy tests with a food challenge
This study checks whether you’re a safe and willing candidate to take part in food allergy clinical studies at one location. It helps decide who can safely undergo the “gold standard” food challenge to confirm or rule out food allergy.
Palo Alto, CaliforniaAges 1 week–90 years - NCT03539705Recruiting
Food Allergy Registry for People of All Ages
This study is a food allergy registry where you can share your experiences and information. It may help researchers better understand food allergies across different ages.
Palo Alto, CaliforniaAges birth–100 years - NCT04828603Recruiting
Study of allergies and sensitization in healthy and allergic people
This study looks at how allergies work by comparing people who may have allergies with people who may not. It may help researchers understand what changes happen when the body becomes “sensitized” to triggers like allergens.
Palo Alto, CaliforniaAges 1 week–90 years - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Los Angeles, CaliforniaAges 12–55 - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
San Francisco, CaliforniaAges 18 years+ - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
La Jolla, CaliforniaAges Up to 2 days - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Los Angeles, CaliforniaAges 16–45 - NCT07216794RecruitingPhase 2
Alendronate trial to reduce hidden HIV
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
San Francisco, CaliforniaAges 18–65 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Los Angeles, CaliforniaAges 12 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Los Angeles, CaliforniaAges 18–75 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
San Francisco, CaliforniaAges 18–60 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
La Jolla, CaliforniaAges 18 years+ - NCT07390955RecruitingPhase 1
Safety study of three anti-HIV antibodies in healthy adults
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
San Francisco, CaliforniaAges 18–55 - NCT06478017RecruitingPhase 2
Belatacept for heart transplant patients
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
Los Angeles, CaliforniaAges 18–71 - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
San Francisco, CaliforniaAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab to prevent lung transplant rejection
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Beverly Hills, CaliforniaAges 12–75 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Los Angeles, CaliforniaAges 13–20 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Los Angeles, CaliforniaAges 18–70 - NCT06970977Recruiting
Chronic sinusitis questionnaire validation study
This study is testing a new questionnaire to better understand chronic sinusitis symptoms. It may help improve how doctors diagnose and treat the condition.
Santa Monica, CaliforniaAges 18 years+ - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Los Angeles, CaliforniaAges 18–70 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
San Francisco, CaliforniaAges 18–75
Allergy trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting allergy studies listed above.
- University of California, San Francisco · 7 studies
- Stanford University · 6 studies
- University of California, Los Angeles (UCLA) · 6 studies
- Cedars-Sinai Medical Center · 4 studies
- UCLA Medical Center · 3 studies
- Bridge HIV CRS · 2 studies
- University of Southern California · 2 studies
- Altman Clinical and Translational Research Institute
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Allergy trials in other states
Common questions
- Are there allergy clinical trials in California?
- Yes. We're currently tracking 37 recruiting allergy studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.